scieee Science in your language
[en] (orig)

PEGylated terbium-based nanorods as multimodal bioimaging contrast agents

Abstract

Diagnostic imaging strongly relies on the use of contrast agents (CAs). In general terms, current CAs present undesirable side effects that encourage researchers and pharmaceutical companies to continually search for safer and more versatile alternatives. Here, we describe the synthesis and characterization of terbium-based nanorods (TbNRs) as a potential alternative to traditional CAs for magnetic resonance imaging (MRI) and X-ray computed tomography (CT). The paramagnetism and high atomic number of Tb provide TbNRs with both magnetic relaxivity and X-ray attenuation capabilities. After surface functionalization with a polyethylene glycol (PEG)-derived ligand, TbNRs showed high colloidal stability in physiological media. Additionally, toxicity studies conducted in cell cultures and zebrafish embryos demonstrated the safety of the as-synthesized TbNRs, thus supporting their potential use as CAs. Lastly, in vivo imaging experiments in mice demonstrated that TbNRs produce remarkable contrast enhancement on both MRI and CT.

Read accessible full text

PEGylated terbium-based nanorods as multimodal bioimaging contrast agents

Author: Caro Salazar, Carlos; Páez-Muñoz, José María; Beltrán, Ana M.; Pernia Leal, Manuel; García Martín, María Luisa
Publisher: American Chemical Society
Year: 2021
DOI: 10.1021/acsanm.1c00569
Source: https://idus.us.es/bitstreams/d0bc72a0-8371-43aa-a741-239d8e105038/download
PEGyla ed Te bium-Based Nano ods as Mul imodal Bioimaging
Con as Agen s
Ca los Ca o, Jose M. Paez-Munoz, Ana M. Bel án, Manuel Pe nia Leal,*
and Ma ía Luisa Ga cía-Ma ín*
Ci e This: ACS Appl. Nano Ma e . 2021, 4, 4199−4207
Read Online
ACCESS Me ics & Mo e A icle Recommenda ions *
sıSuppo ing In o ma ion
ABSTRACT: Diagnos ic imaging s ongly elies on he use o
con as agen s (CAs). In gene al e ms, cu en CAs p esen
undesi able side effec s ha encou age esea che s and pha ma-
ceu ical companies o con inually sea ch o sa e and mo e
e sa ile al e na i es. He e, we desc ibe he syn hesis and
cha ac e iza ion o e bium-based nano ods (TbNRs) as a
po en ial al e na i e o adi ional CAs o magne ic esonance
imaging (MRI) and X- ay compu ed omog aphy (CT). The
pa amagne ism and high a omic numbe o Tb p o ide TbNRs
wi h bo h magne ic elaxi i y and X- ay a enua ion capabili ies.
A e su ace unc ionaliza ion wi h a polye hylene glycol (PEG)-
de i ed ligand, TbNRs showed high colloidal s abili y in
physiological media. Addi ionally, oxici y s udies conduc ed in
cell cul u es and zeb afish emb yos demons a ed he sa e y o he as-syn hesized TbNRs, hus suppo ing hei po en ial use as CAs.
Las ly, in i o imaging expe imen s in mice demons a ed ha TbNRs p oduce ema kable con as enhancemen on bo h MRI and
CT.
KEYWORDS: Ra e-ea h nanopa icles, e bium, MRI, CT, con as agen s, mul imodal imaging
■INTRODUCTION
Imaging-based diagnosis has long since become an essen ial
ool o daily clinical p ac ice. Among he diffe en in i o
imaging modali ies, MRI and CT s and ou o hei abili y o
ende de ailed 3D ana omical in o ma ion along wi h
unc ional in o ma ion, especially in he case o MRI.
1
Al hough he use o con as agen s (CAs) is o en
unnecessa y, in ce ain si ua ions, hey a e essen ial o he
p ope isualiza ion o a pa icula egion o in e es o o ge
ele an unc ional in o ma ion, such as pe usion o diffusion
pa ame e s.
2
The mos commonly used in a enous CAs a e
gadolinium- and iodine-based compounds o MRI and CT,
espec i ely.
3,4
Gd chela es a e ou inely used as MRI CAs o
gene a e posi i e con as in T1-weigh ed images as a esul o
sho ening he longi udinal elaxa ion ime (T1) p oduced by
he Gd ca ions on he p o ons o he nea by wa e molecules.
As o iodine de i a i es, hey a e used as CT CAs owing o he
high a omic numbe o iodine (Z= 53), which s ongly
co ela es wi h he X- ay a enua ion coefficien . Image
con as in CT is p oduced by diffe ences in he X- ay
a enua ion o issues and, he e o e, he p esence o iodine
de i a i es will po en ia e image con as by inc easing he
a enua ion coefficien o he issues whe e hey accumula e.
5
Al hough Gd chela es and iodina ed compounds a e s ill
widely used a p esen , hey ha e some impo an limi a ions.
On he one hand, Gd chela es can p oduce oxic effec s caused
by he unexpec ed elease o Gd3+ and subsequen accumu-
la ion in diffe en issues,
6−8
whe eas iodina ed compounds
can cause alle gic eac ions, con as -induced neph opa hy, o
hype hy oidism.
9−11
On he o he hand, bo h ypes o CAs
exhibi sho blood hal -li es since hey a e apidly exc e ed by
enal fil a ion due o hei small size and, he e o e, hei use is
limi ed o applica ions in which long ci cula ion imes a e no
equi ed.
Cu en ad ances in medical imaging aim o inc ease
diagnos ic accu acy h ough diffe en s a egies, such as
mul imodal imaging e alua ions. In his scena io, nano-
medicine plays a key ole, hanks o he eno mous possibili ies
i offe s o p oduce new nanoscale ma e ials wi h imp o ed
p ope ies and unc ionali ies.
12
Thus, nume ous new nano-
scale CAs wi h g ea po en ial o imp o e he diagnos ic
accu acy o MRI and CT ha e been p oduced o e he pas ew
yea s.
13,14
Among hem, nanos uc u es based on a e ea h
Recei ed: Feb ua y 24, 2021
Accep ed: Ma ch 10, 2021
Published: Ma ch 19, 2021
A iclewww.acsanm.o g
© 2021 Ame ican Chemical Socie y 4199
h ps://doi.o g/10.1021/acsanm.1c00569
ACS Appl. Nano Ma e . 2021, 4, 4199−4207
Downloaded ia UNIV DE SEVILLA on Oc obe 18, 2023 a 08:23:31 (UTC).
See h ps://pubs.acs.o g/sha ingguidelines o op ions on how o legi ima ely sha e published a icles.
(RE) elemen s ha e a ac ed a g ea deal o a en ion because
o hei unique physicochemical p ope ies, which p o ide
hem wi h g ea po en ial o bioimaging applica ions.
15
Thus,
he ou s anding magne ic p ope ies o se e al RE elemen s,
such as Gd, Ho, Dy, o Tb, ha e been exploi ed o he
de elopmen o a new gene a ion o nanos uc u ed CAs o
MRI.
16−24
Likewise, lan hanide-based nanos uc u es a e also
sui able o CT imaging, hanks o he high a omic numbe (Z)
o hese elemen s, which allows hem o efficien ly abso b X-
ays.
25,26
The as majo i y o hese s udies use he lan hanide
as a dopan agen and no as he main componen o he
nanos uc u ed ma e ial. Ye , o he RE-based s uc u es,
mos ly lan hanide oxide nanopa icles (NPs), ha e also been
explo ed as CAs o in i o imaging. Among hem, Gd-oxide
NPs as MRI CAs a e he mos widely s udied.
27−30
Rega ding
Tb-oxide NPs, Ma asini e al.
31
ecen ly epo ed he syn hesis
o ul asmall pa amagne ic NPs based on se e al lan hanide
oxides, including Tb oxide. This wo k shows he po en ial o
hese NPs as MRI CAs, al hough no in i o e idence has been
epo ed so a . Indeed, i is wo h no ing he e ha a key aspec
lacking in many o hese s udies is de ailed in i o
cha ac e iza ion ha demons a es he eal po en ial o hese
nanos uc u es as CAs. In addi ion o high biocompa ibili y,
NP-based CAs mus be able o escape he mononuclea
phagocy e sys em and emain in ci cula ion long enough o
efficien ly each hei a ge , especially in umo imaging.
Howe e , many o he RE-based CAs, pa icula ly hose ha
use RE elemen s as he doping agen , exhibi la ge hyd o-
dynamic diame e s (HDs), usually abo e 100 nm, which in i o
lead o apid li e up ake, limi ing hei applicabili y as
CAs.
23,29,32
On he o he hand, long ci cula ion imes a e
de e mined no only by he size o he NPs bu also by hei
coa ing. In his ega d, s eal h polyme s such as polye hylene
glycol (PEG) ha e been shown o efficien ly p olong blood
ci cula ion imes.
33
He e, we epo he syn hesis o e bium-
based nano ods (TbNRs) wi h sizes o 2 ×9 nm wi h high
colloidal s abili y and excellen luminescen , magne ic, and X-
ay a enua ion p ope ies. These TbNRs we e well dispe sed
in physiological medium by a simple ligand exchange wi h a
ca echol-de i ed PEG ligand. The cy o oxici y o he esul ing
PEGyla ed TbNRs (PEG−TbNRs) was assessed in i o using
diffe en assays, including MTT, li e-dead, and flow cy ome y,
and in i o using zeb afish emb yos. Then, in i o imaging
s udies we e conduc ed in mice o de e mine he sui abili y o
PEG−TbNRs as CT and MRI CAs.
■EXPERIMENTAL SECTION
Ma e ials. Comme cial eagen s and sol en s we e pu chased om
acc edi ed supplie s (Sigma-Ald ich, Fishe Scien ific, and Ac os
O ganics): e bium(III) chlo ide, oleic acid 99%, sodium olea e, 1-
oc adecene, PEG, gallic acid, 4-dime hylaminopy idine, ie hylamine,
dicyclohexylca bodiimide (DCC), ni ic acid (HNO3), sodium sul a e
(Na2SO4), hyd ochlo ic acid (HCl), 3-[4,5-dime hyl hiazol-2yl]-2,5-
diphenyl e azolium b omide (MTT), T i on X-100, TO-PRO-3
iodine, DAPI (4′,6-diamidino-2-phenylindole), Roswell Pa k Memo-
ial Ins i u e (RPMI) medium, and phospha e buffe ed saline (PBS).
The sol en s: e hanol, oluene, chlo o o m, hexane, ace one,
dime hylsulphoxide (DMSO), e ahyd o u an, and dichlo ome hane
we e used in he anhyd ous o m and wi h HPLC g ade; Milli-Q
wa e was used (Millipo e, fil e po e size 0.22 μM, 18.2 MΩ).
Syn hesis o TbNRs. Syn hesis o Tb Olea e. Fo he syn hesis o
Tb olea e, we used an adap ed e sion o he p o ocol epo ed by Liu
e al.
24
In b ie , a mix u e o 1.87 g o e bium chlo ide (7.05 mmol)
and 4.75 g o sodium olea e (15.60 mmol) was dissol ed in 7 mL o
dis illed wa e , 10 mL o e hanol, and 17 mL o hexane. This solu ion
was efluxed o 4 h unde an ine a mosphe e, cooled o oom
empe a u e and ans e ed in o a sepa a ion unnel. The o ganic
laye , which con ains he desi ed e bium olea e, was washed se e al
imes using dis illed wa e . The hexane was e apo a ed using a
o a apo .
Syn hesis o TbNRs. A o al o 0.511 g (0.51 mmol) o e bium
olea e, along wi h 0.250 g (0.89 mmol) o oleic acid and 3.5 mL o 1-
oc adecene was hea ed a 320 °C o 1 h in an ine a mosphe e
(Scheme 1). Then, he mix u e was cooled down o oom
empe a u e and washed se e al imes wi h a mix u e o e hanol
and ace one (1:1) as p ecipi a ing agen s, and subsequen ly
cen i uged (10 min a 5.000 pm). TbNRs we e hen esuspended
in oluene.
Func ionaliza ion o TbNRs. The de ailed p ocedu e conce ning
he ligand syn hesis is desc ibed in he Suppo ing In o ma ion.In
b ie , a solu ion con aining 1.0 mL o TbNRs (10 g/L), 1.0 mL o he
ligand GA-PEG3000-OH (0.1 M in CHCl3), and 50 μLo
ie hylamine was pu in a sepa a ing unnel. This mix u e was
shaken gen ly and hen dilu ed by adding 5 mL o oluene, 10 mL o
ace one, and 5 mL o Milli-Q wa e . Subsequen ly, his mix u e was
shaken, he aqueous laye collec ed in a ound-bo om flask, and he
emaining o ganic sol en s o ae apo a ed. The esul ing wa e -
soluble PEG−TbNRs we e pu ified using 100 kDa cu -offcen i uge
fil e s a 450 c un il he ee ligand was comple ely emo ed. Then,
he PEG−TbNRs we e dilu ed in he co esponding media and
cen i uged du ing 5 min a 150 c .
Cha ac e iza ion. T ansmission Elec on Mic oscopy. T ans-
mission elec on mic oscopy (TEM) and scanning-TEM (STEM)
images we e ob ained on a FEI TALOS F200 (FEI, Hillsbo o, OR,
USA) ope a ing a 200 kV accele a ing ol age and equipped wi h
Supe -X ene gy-dispe si e X- ay spec ome y (EDX). Composi ional
analyses o he samples we e pe o med by he combina ion o high-
angle annula da k-field images (HAADF) and EDX acquisi ions in
TEM and STEM modes (0.2 s dwell ime and spa ial d i co ec ion).
Sample p epa a ion consis ed o d opwise adding TbNR solu ion (∼1
g/L o Tb) on o a ca bon-coa ed coppe g id and le ing i d y. The
leng h and diame e o TbNRs we e calcula ed as he a e age o a
hund ed TbNRs measu ed.
Scheme 1. Syn hesis P ocedu e o TbNRs
ACS Applied Nano Ma e ials www.acsanm.o g A icle
h ps://doi.o g/10.1021/acsanm.1c00569
ACS Appl. Nano Ma e . 2021, 4, 4199−4207
4200
UV− is Spec oscopy. The UV− is spec a we e egis e ed on a
Ca y 100 (Agilen , Wal ham, MA, U.SA) spec ome e using a qua z
ay wi h 1 cm ligh pa h.
Fluo escence Spec oscopy. The fluo escence spec a we e
eco ded wi h an Edinbu gh Ins umen s FLS920 (Edinbu gh, U.K)
spec ome e wi h a qua z ay (ligh pa h = 1 cm).
Vib a ing Sample Magne ome e . The analysis o he magne -
iza ion beha io was pe o med on a ib a ing sample magne ome e
(VSM) (Mic oMag 3900, P ince on Measu emen s Co p., U.S.A)
using magne ic fields anging om −1 o 1 T a 5 and 300 K.
Dynamic Ligh Sca e ing. PEG−TbNR size dis ibu ion was
analyzed using a Ze asize Nano ZS90 (Mal e n Ins umen s,
Mal e n, Wo ces e shi e, U.K). PEG−TbNRs we e dispe sed in
PBS o cul u e medium a a final concen a ion o 50 mg/L(Tb).
ZEN0118-low- olume disposable sizing cu e es we e used o hese
measu emen s; 2.420 was se as he e ac i e index wi h an angle o
de ec ion o 173°backsca e (NIBS de aul ). The measu emen ime
was de e mined au oma ically. Th ee measu emen s we e pe o med
pe sample. The size dis ibu ion was de e mined using he numbe
mean. The analysis was done acco ding o he gene al-pu pose
(no mal esolu ion) model.
Fou ie T ans o m In a ed Spec oscopy. Fou ie ans o m
in a ed spec oscopy (FTIR) spec oscopy was pe o med on a
JASCO FTIR-4100 equipped wi h an ATR accesso y (MIRacle ATR,
PIKE Technologies) coupled o a me cu y cadmium ellu ide (MCT)
de ec o cooled wi h liquid ni ogen. Spec a acquisi ion was
pe o med om 4000 o 800 cm−1(4 cm−1 esolu ion, 50 scans).
Nuclea Magne ic Resonance Spec oscopy. The 1HNMR
spec um o he ligand p epa ed in CDCl3was acqui ed on a B uke
400 MHz nuclea magne ic esonance (NMR) sys em (B uke
BioSpin, Rheins e en, Ge many).
T ans e sal Relaxi i ies ( 2). 2was measu ed in PBS a 1.44 and
9.4 T using concen a ions o PEG−TbNRs anging om 2 o 0.2
mM Tb. T2 alues a 1.44 T we e de e mined on a B uke Minispec
MQ-60 (B uke BioSpin, Rheins e en, Ge many) using a Ca l−
Pu cell−Meiboom−Gill (CPMG) sequence. T2 alues a 9.4 T we e
measu ed on a B uke Biospec MRI spec ome e (B uke Biospec,
B uke BioSpin, E lingen, Ge many) equipped wi h a 40 mm
quad a u e esona o and 400 mT m−1field g adien s. T2 alues we e
measu ed using a 64-echo CPMG imaging sequence (TE alues
be ween 7.5 and 640 ms).
T ans e se elaxi i y, 2, was de e mined as he slope o he linea
fi o 1/T2o e [Tb].
Induc i ely Coupled Plasma High-Resolu ion Mass Spec osco-
py. Tb concen a ion was de e mined on a NexION ICP−HRMS
(Pe kinElme , Wal ham, MA, U.SA). In b ie , 25 μL o he TbNR
solu ion was dilu ed wi h 2.5 mM aqua egia. This mix u e was le
o e nigh and hen dilu ed up o 25 mL wi h wa e .
Cell Cul u e. N13 mouse mic oglial cells we e g own in RPMI
medium supplemen ed wi h 10% FBS, 2 mM L-glu amine, and 1%
penicillin/s ep omycin a 37 °C and 5% CO2.
Cy o oxici y. The cy o oxici y o PEG−TbNRs was assessed in
N13 cells by he MTT assay (de ails a e gi en in he Suppo ing
In o ma ion).
Cell Mo phology S udies. These s udies we e pe o med using a
Pe kinElme ope e a high con en imaging sys em, which allowed us
o e alua e cell mo phology and calcula e he pe cen age o cell dea h.
Fu he de ails a e gi en in he Suppo ing In o ma ion.
Te a ogenici y Assay. Wild- ype zeb afish we e used o hese
expe imen s. A day 0, hey we e ou c ossed, and hen, he emb yos
we e collec ed and incuba ed in E3 medium o 4 h a 28 °C.
Un e ilized eggs we e disca ded. Those emb yos ha de eloped
p ope ly we e exposed o diffe en concen a ions o PEG−TbNRs in
E3 medium. Eggs we e deposi ed in eigh -well Pe i dishes (∼30 eggs
in 4 mL). The ha ching a e, mal o ma ions, and su i al we e
analyzed a 24, 48, and 96 h o PEG−TbNRs exposu e.
Animals. BALB/c mice (male, ca. 22 g weigh , n= 3), p o ided by
Jan ie Labs (Le Genes -Sain -Isle, F ance), we e used in all in i o
imaging expe imen s. The expe imen s we e ca ied ou in acco dance
wi h ou local e hics commi ee guidelines and we e consis en wi h
he na ional egula ions o he use and ca e o expe imen al animals
(R.D. 53/2013). P io o imaging expe imen s, mice we e
Figu e 1. TEM (a) and EDX (b) images o TbNRs be o e unc ionaliza ion. TEM (c) and STEM (d) images o PEGyla ed TbNRs. Inse shows a
highe -magnifica ion image (scale ba co esponds o 10 nm).
ACS Applied Nano Ma e ials www.acsanm.o g A icle
h ps://doi.o g/10.1021/acsanm.1c00569
ACS Appl. Nano Ma e . 2021, 4, 4199−4207
4201
anes he ized (1% isoflu ane), and a ca he e was in oduced in o hei
ail ein o in a enous adminis a ion o he PEG−TbNRs. Then,
he animals we e ans e ed o he imaging sys em (CT o MRI). The
PEG−TbNRs we e adminis e ed in a enously (10 mg o Tb pe kg).
In Vi o and In Vi o CT. CT images we e ob ained on a B uke
Albi a sys em (B uke Biospec, B uke BioSpin, E lingen, Ge many)
using he ollowing pa ame e s: 35 μm X- ay ocal spo size
(nominal), 45 kVp ene gy, wo king a 400 μA. A enua ion alues
we e exp essed in Hounsfield uni s, wi h he scale adjus ed o be e
isualize so issues, o e exposing he bones. Li e and kidney
pha macokine ics we e calcula ed om he a e age alues wi hin he
same egions o in e es (ROIs) a diffe en expe imen al imes.
In Vi o MRI. MRI s udies we e pe o med on he 9.4 T B uke
Biospec sys em desc ibed in he T ans e sal elaxi i ies sec ion by
ollowing he p o ocol desc ibed by us elsewhe e.
34
In b ie , high-
esolu ion T2-weigh ed images and a sequence o as T2-weigh ed
images we e acqui ed and analyzed o cha ac e ize he sho - e m
pha macokine ics (fi s 30 min). Then, quan i a i e T2maps we e
acqui ed a 0, 1, 24, 48, and 168 h o e alua e long- e m
biodis ibu ion and pha macokine ics.
His ology. A 168 h pos injec ion o he PEG−TbNRs, mice we e
eu hanized and he kidneys, spleen, and li e we e collec ed. Tissue
a chi ec u e was assessed by ligh mic oscopy o hema oxylin and
eosin (H&E)-s ained issue sec ions. De ails a e p o ided in he
Suppo ing In o ma ion.
S a is ical Analysis. The SPSS package (SPSS Inc., Chicago,
Illinois) was used o he s a is ical analysis. Diffe ences be ween
diffe en expe imen al condi ions we e de e mined by s uden ’s - es
o one-way analysis o a iance (ANOVA), wi h a significance le el o
0.05.
■RESULTS AND DISCUSSION
Syn hesis, Cha ac e iza ion, and Func ionaliza ion o
TbNRs. TbNRs we e syn hesized by he mal decomposi ion o
e bium−olea e in he p esence o oleic acid in 1-oc adecene.
The mo phology and size o he syn hesized TbNRs we e
examined by TEM and EDX. The as-p epa ed pa icles showed
an elonga ed shape o a ound 9.0 nm in leng h and 2.1 nm in
wid h. In e es ingly, hese elonga ed pa icles we e o ganized
in elonga ed supe s uc u es o a ound 80.2 nm in leng h and
9.2 nm in wid h (Figu es 1a and S1). The o ma ion o hese
assemblies o NPs occu ed du ing he syn hesis p ocess, likely
due o he diffe en eac i i y along he ods. These assemblies
o oleic acid-capped NPs we e ligand exchanged by ca echol-
de i ed PEG ligands, esul ing in wa e -soluble assemblies wi h
a s uc u e simila o ha o he as-syn hesized TbNRs, as
shown in he TEM images. The e o e, he gen le ligand
exchange p ocedu e was no sufficien o disassemble he NPs,
p obably due o he high ene gy o in e ac ion be ween hem.
The as-p epa ed TbNRs we e capped by oleic acid
su ac an s, gi ing a hyd ophobic cha ac e o he nanoma e i-
al. Thus, o make hem biocompa ible, TbNRs we e ans-
e ed o aqueous media by ollowing a p e iously epo ed
ligand exchange me hod,
35
using a ca echol-de i ed PEG−OH
ligand. As p e iously shown, ca echol ancho s s ongly in e ac
wi h he i on oxide NP su ace ia hei phenolic hyd oxyl
g oups.
36
These ancho s o m a s able 5-membe ed ing
complex wi h he Fe ca ion. Simila ly, lan hanide ca echola e
complexes a e likely o med om i alen lan hanide ca ions
and ca echol-de i ed ligands. Then, he bi-den a e ca echol
ancho o he ligand would eac wi h he Tb a he su ace o
he NRs o ming a s able complex simila o he e bium−
ca echola e complex [Tb2(ca )3] p oduced in solu ion.
37,38
Cha ac e iza ion o PEGyla ed TbNRs. PEG−TbNRs
we e ho oughly cha ac e ized by diffe en physicochemical
echniques o de e mine hei mo phology, size, op ical
p ope ies, magne ic p ope ies, and colloidal s abili y. The
o iginal mo phology and sizes o he p is ine NRs we e
p ese ed a e ligand exchange, as confi med by TEM and
STEM (Figu es 1c,d and S1). Mo eo e , he a achmen o he
PEGyla ed ligand o he su ace o he TbNRs was confi med
by FTIR spec oscopy (Figu e S2). Addi ionally, hese
unc ionalized TbNRs we e e y s able in wa e wi hou any
sign o p ecipi a ion o e ime, u he confi ming he success
in inco po a ing he PEGyla ed ligands on he su ace o he
TbNRs. Fu he analysis by dynamic ligh sca e ing (DLS)
showed he high s abili y o PEG−TbNRs in physiological
media, specifically in PBS and cell cul u e medium. PEG−
TbNRs showed HDs a ound 75 nm in PBS, and sligh ly lowe
(∼60 nm) in cell cul u e medium. A e 24 h, he HDs o
PEG−TbNRs inc eased by a ound 30% and hen emained
s able h oughou he measu emen ime (1 week). This
beha io demons a es he s abili y o PEG−TbNRs in
physiological media and also ha no agg ega es we e o med
du ing ligand exchange (Figu e S3).
REs also show in e es ing op ical p ope ies, which a e
go e ned by he elec on configu a ion and can be
cha ac e ized by UV− is and pho oluminescence (PL) spec-
oscopy. Thus, he op ical abso p ion in he UV egion o REs
can o igina e om ansi ions 4 →5d. The e o e, he peak
obse ed a 277 nm in he UV− is spec um could be assigned
o he 4 8→4 75d ansi ion, which no mally appea s a mo e
han 200 nm in he case o Tb ions (Figu e 2).
39
The PL
emission spec um o he TbNRs dispe sed in oluene a oom
empe a u e is shown (Figu e 2). The emission spec um o
TbNRs unde 325 nm exci a ion displayed ou emission
peaks, which could be assigned o he elec on ansi ions om
5D4→7F6(490 nm), 5D4→7F5(546 nm), 5D4→7F4(583
nm), and 5D4→7F3(620 nm). Among hese ansi ions, he
g een emission (546 nm) appea ed as he s onges , which is in
ag eemen wi h he Judd−O el heo y.
24
Addi ionally, PEG−TbNRs we e e alua ed as po en ial CAs
o in i o imaging, specifically o CT and MRI. The abili y o
Figu e 2. (a) UV− is spec um o PEG−TbNRs. (b) Fluo escence emission spec a o PEG−TbNRs.
ACS Applied Nano Ma e ials www.acsanm.o g A icle
h ps://doi.o g/10.1021/acsanm.1c00569
ACS Appl. Nano Ma e . 2021, 4, 4199−4207
4202
PEG−TbNRs o be used as CT CA was de e mined by
measu ing he X- ay a enua ion. In e es ingly, he slope o he
linea fi o he X- ay a enua ion e sus he PEG−TbNRs
concen a ion was 21.4 HU mM−1[Tb], which is 10- old
highe han ha ob ained o he comme cial CA iohexol (2.69
HU mM−1)(Figu e 3b).
40
On he o he hand, he magne ic
p ope ies o PEG−TbNRs we e s udied o e alua e hei
po en ial as MRI CAs. Fi s , he magne ic hys e esis loop
measu emen s by he VSM showed ha PEG−TbNRs exhibi
supe pa amagne ic beha io a 5 K and pa amagne ic a 300 K
(Figu e 3a). Then, hei magne ic ans e se elaxi i y, 2, was
de e mined a 1.44 and 9.4 T. PEG−TbNRs showed 2 alues
o 10.4 mM−1•s−1and 48.5 mM−1•s−1(Figu e 3c) a low and
high magne ic fields, espec i ely. The e o e, we can conclude
ha ou PEG−TbNRsbeha easmul imodalimaging
nanosys ems o op ical imaging, CT, and MRI. Howe e ,
he emission wa eleng h o hese PEG−TbNRs, a ound 540
nm, limi s hei applicabili y in i o in op ical imaging due o
he high issue au ofluo escence a ha wa eleng h,
41
oge he
wi h weak issue pene a ion. On he con a y, hei excellen
X- ay a enua ion and magne ic elaxa ion p ope ies make
hem e y p omising CT and MRI CAs o bioimaging.
In Vi o Cy o oxici y Assessmen . The e alua ion o he
cy o oxici y o new nanoma e ials designed o biological
applica ions is a c ucial s ep ha equi es an exhaus i e
analysis. The e o e, we ca ied ou a de ailed analysis including
mul iple assays, namely, cell mo phology, li e-dead, and MTT
assays. These assays we e pe o med on he mouse mic oglial
cell line, N13. A e exposu e o g owing concen a ions o
PEG−TbNRs, om 0.1 o 100 μg/mL o Tb, N13 cells did no
show e idence o mo phological changes, e en o he highes
concen a ion e alua ed (Figu es 4a−c and S4). Fu he mo e,
he o al numbe o cells pe well emained unal e ed o all he
concen a ions es ed (Figu es 4dandS5). Indeed, he
pe cen age o dead cells emained a ound 0%, wi hou a
s a is ically significan inc ease in all cases (Figu es 4e and S5).
Finally, no s a is ically significan effec on mi ochond ial
ac i i y was obse ed wi h he MTT assay (Figu e 4 ). These
esul s demons a e ha PEG−TbNRs exhibi excellen
cellula biocompa ibili y, suppo ing hei po en ial o in i o
applica ions. Howe e , in i o oxici y depends on many
diffe en ac o s ha canno be e alua ed in cell cul u es.
The e o e, be o e p oceeding wi h in i o expe imen s on mice,
oxici y was also assessed in i o using zeb afish emb yos.
Figu e 3. (a) hys e esis loop o PEG-TbNRs measu ed a 5 K (black) and 300 K (blue); (b) X- ay a enua ion measu ed as he linea ela ionship
be ween he in ensi y o he CT images and he concen a ion o Tb in he PEG−TbNR solu ions; (b); (c) elaxa ion a e (1/T2) s he
concen a ion o Tb in he PEG−TbNR solu ions measu ed a 1.44 T (black do s) and 9.4 T ( ed do s), and he linea fi s (black and ed lines)
whose slopes co espond o he ans e se elaxi i ies ( 2) o PEG−TbNRs a bo h magne ic fields.
Figu e 4. Op ical mic oscopy images o N13 cells: (a) nega i e con ol, (b) posi i e con ol, (c) cells exposed PEG−TbNRs (100 μg/mL). Images
co espond o he me ging o TO-PRO-3 iodine ( ed), DAPI (blue), and b igh field (g ay). Scale ba s co espond o 100 μm. Ba cha s
co espond o (d) o al numbe o cells/well, (e) pe cen age o dead cells, and ( ) cell iabili y (MTT assay) a e exposu e o inc easing
concen a ion o PEG−TbNRs o 24 h.
ACS Applied Nano Ma e ials www.acsanm.o g A icle
h ps://doi.o g/10.1021/acsanm.1c00569
ACS Appl. Nano Ma e . 2021, 4, 4199−4207
4203

Te a ogenici y Assessmen on Zeb afish Emb yos.
Te a ogenici y o PEG−TbNRs was e alua ed in zeb afish
emb yos, as p e iously desc ibed.
42
The su i al and ha ching
a es o zeb afish emb yos exposed o g owing concen a ions
o PEG−TbNRs (0.1, 1, 10, 50, and 100 μg/mL o Tb) we e
assessed a diffe en ime poin s a e e iliza ion. A e 24 h
pos exposu e, PEG−TbNRs we e clea ly obse ed o be
in e ac ing wi h he cho ion o he emb yos (Figu e S6a).
Rega ding he ha ching p ocess, bo h con ol emb yos and
hose exposed o 48 h o PEG−TbNRs showed 100%
ha ching (Figu e S6b). These esul s ag ee wi h ha ching a es
epo ed o no mal zeb afish emb yos.
43
In addi ion, nei he
mo ali y no mal o ma ions we e obse ed a any ime poin
in he emb yos exposed o PEG−TbNRs (Figu es 5 and S7).
In Vi o CT and MRI S udies. CT imaging s udies showed
an inc emen o 5.5 ±2.1 HU in he li e 1 h
pos adminis a ion o PEG−TbNRs (10 mg o Tb pe kg),
which inc eased up o 12.1 ±3.1 a e 24 h (Figu e 6). Then,
he ΔHU alues dec eased, being 10.4 a 24 h and 6.1 a 168 h.
The e o e, he maximal accumula ion was de ec ed a 24 h, and
hen, PEG−TbNRs we e slowly clea ed om he li e .
Impo an ly, hese esul s we e ob ained wi h an injec ion
dose app oxima ely 50 imes lowe han ha ecommended o
iohexol, which is 430 mg pe kilog am o body imaging
applica ions.
44
In i o biodis ibu ion and pha macokine ics o he PEG−
TbNRs we e also e alua ed by MRI. Sho - e m pha macoki-
ne ics by dynamic T2imaging showed ha he PEG−TbNRs
we e apidly aken up by he li e , eaching a alue o 50% o
ela i e enhancemen du ing he fi s 30 min a e he
in a enous adminis a ion o PEG−TbNRs (10 mg o Tb)
(Figu e 7a,b).
No significan accumula ion was obse ed in he es o he
o gans. Mo eo e , long- e m pha macokine ics showed a
maximal T2dec ease (ΔT2o 7.1 ms) a 24 h a e
adminis a ion, in ag eemen wi h he CT esul s shown
abo e. A simila end was obse ed in he kidneys, whe e he
maximum T2dec ease (ΔT2o 5.9 ms) was eached a 24 h.
A e 48 h, he kidneys eco e ed hei ini ial T2 alues,
whe eas he li e only showed a sligh T2 eco e y, in
ag eemen wi h he slow li e clea ance desc ibed in he CT
s udies (Figu e 7c).
Quan i a i e E alua ion o Ci cula ing Li e ime o
PEG−TbNRs in he Bloods eam. Tb con en in blood and
he li e a 1 and 24 h was quan ified by ICP−MS (Figu e 8).
The concen a ion o Tb in blood was 2.3 and 1.4 mg/L a 1
and 24 h pos adminis a ion, which co esponds o 10 and 6%
o he injec ed dose, espec i ely. These esul s confi med he
long blood hal -li e o he PEG−TbNRs. As expec ed, an
opposi e end was obse ed in he li e , showing 16.2 mg/kg
o issue a 1 h and 34.5 mg/kg o issue a 24 h, espec i ely.
Thus, he ICP esul s a e in e y good ag eemen wi h he CT
and MRI esul s, demons a ing ha PEG−TbNRs ha e long
blood esidence ime, being s ill p esen a 24 h, and ha hey
unde go slow hepa ic clea ance. Blood esidence ime is o
u mos impo ance o some in i o applica ions, in pa icula
o umo a ge ing. Efficien umo a ge ing, whe he passi e,
ia enhanced pe meabili y and e en ion (EPR) effec , o
ac i e, has been shown o equi e long ci cula ion imes.
45
The e o e, he ICP−MS esul s, which a e in good ag eemen
wi h he MRI findings and wi h he long-ci cula ing na u e o
ou PEG−TbNRs, u he suppo he g ea po en ial o hese
nanosys ems o in i o applica ions, specifically o cance
imaging.
In Vi o Toxici y Assessmen . Finally, po en ial ha m
caused by he in a enous adminis a ion o PEG−TbNRs was
assessed his ologically and also by ollowing he weigh p ofile
o he animals. H&E s aining was ca ied ou on issue samples
o he li e , kidneys, and spleen a 168 h pos adminis a ion o
PEG−TbNRs. The li e sec ions o he animals injec ed wi h
PEG−TbNRs esembled hose injec ed wi h PBS. No e idence
o acu e and subacu e li e inju y, such as acuola ed swelling
o he hepa ocy es’cy oplasm, was obse ed in he li e
sec ions (Figu e S8). Likewise, no subs an ial changes we e
obse ed in he kidneys o he animals injec ed wi h PEG−
TbNRs when compa ed o con ol animals. Kidneys exhibi ed
egula in ac b ush bo de s and glome uli a ound he
Bowman’s capsule (Figu e S8).
46
Finally, he spleen also
p esen ed no mal his ological ea u es wi h unal e ed ed and
whi e pulp, which is cha ac e is ic o hei no mal a chi ec u e.
Rega ding he weigh p ofile, a ansien dec ease in body
weigh was obse ed, wi h a maximum diffe ence be ween
g oups a 24 h a e he adminis a ion o PEG−TbNRs.
Howe e , a e 168 h, he animals egained hei no mal
weigh , indica ing he absence o oxic effec s (Figu e S9).
Figu e 5. Mo phological analysis o zeb afish emb yos exposed o
g owing concen a ions o PEG−TbNRs a diffe en ime poin s (24,
48, and 96 h).
Figu e 6. Rep esen a i e in i o CT images a diffe en ime poin s (0,
1, 24, 48, and 168 h) a e he injec ion o PEG−TbNRs. The li e
has been highligh ed o be e isualiza ion. Values a e in Hounsfield
uni s and he scale adjus ed o be e isualiza ion o so issues,
o e exposing he bones.
ACS Applied Nano Ma e ials www.acsanm.o g A icle
h ps://doi.o g/10.1021/acsanm.1c00569
ACS Appl. Nano Ma e . 2021, 4, 4199−4207
4204
■CONCLUSIONS
We epo he syn hesis o PEGyla ed TbNRs wi h po en ial
applica ion as mul imodal imaging CAs. TbNRs we e
syn hesized by he mal decomposi ion o he as-p epa ed
Tb−olea e. Then, TbNRs we e success ully unc ionalized
using a ca echol-de i ed PEG ligand o ende wa e -s able
TbNRs. These PEG−TbNRs showed high colloidal s abili y in
diffe en media, absence o oxici y in i o in cell cul u es and
in i o in zeb afish emb yos, and excellen p ope ies as CT
and MRI CAs. On he o he hand, a e in a enous injec ion
in mice, he PEG−TbNRs showed excellen in i o imaging
con as bo h in CT and MRI, long blood esidence ime,
being s ill p esen a e 24 h, and effec i e hepa ic clea ance.
Al oge he , hese esul s demons a e he high po en ial o
PEG−TbNRs as in i o mul imodal CAs.
■ASSOCIATED CONTENT
*
sıSuppo ing In o ma ion
The Suppo ing In o ma ion is a ailable ee o cha ge a
h ps://pubs.acs.o g/doi/10.1021/acsanm.1c00569.
De ails on he expe imen al sec ion, TEM his og ams,
FTIR, DLS, UV− is, PL, VSM, in i o CT e alua ion,
magne ic elaxi i y, in i o cy o oxici y, in i o oxici y,
and in i o side effec s in oden s (PDF)
■AUTHOR INFORMATION
Co esponding Au ho s
Manuel Pe nia Leal −Depa amen o de Química O gánica y
Fa macéu ica, Facul ad de Fa macia, Uni e sidad de Se illa,
Se ille 41012, Spain; o cid.o g/0000-0001-8160-0574;
Email: [email p o ec ed]
Ma ía Luisa Ga cía-Ma ín−BIONAND−Cen o Andaluz
de Nanomedicina y Bio ecnología (Jun a de Andalucía-
Figu e 7. In i o pha macokine ics o in a enously injec ed PEG−TbNRs in BALB/c mice: (a) sho - e m pha macokine ics in he li e ; (b)
sho - e m pha macokine ics in he kidneys; (c) T2-weigh ed MR images a diffe en imes pos adminis a ion o PEG-TbNRs; (d) T2 a ia ion in
diffe en issues de e mined om in i o T2maps ( alues co espond o a e age T2and ΔT2 om 3 animals).
Figu e 8. ICP−MS quan ifica ion o Tb con en a 1 and 24 h pos in a enous injec ion o PEG−TbNRs. (a) Absolu e Tb concen a ion, (b)
ela i e Tb concen a ion (% o he injec ed dose). E o ba s co espond o s anda d de ia ion (n= 3).
ACS Applied Nano Ma e ials www.acsanm.o g A icle
h ps://doi.o g/10.1021/acsanm.1c00569
ACS Appl. Nano Ma e . 2021, 4, 4199−4207
4205
Uni e sidad de Málaga), Málaga 29590, Spain; Biomedical
Resea ch Ne wo king Cen e in Bioenginee ing, Bioma e ials
&Nanomedicine (CIBER-BBN), Málaga 29590, Spain;
o cid.o g/0000-0002-2257-7682; Email: mlga cia@
bionand.es
Au ho s
Ca los Ca o −BIONAND−Cen o Andaluz de
Nanomedicina y Bio ecnología (Jun a de Andalucía-
Uni e sidad de Málaga), Málaga 29590, Spain;
o cid.o g/0000-0003-4758-3816
Jose M. Paez-Munoz −BIONAND−Cen o Andaluz de
Nanomedicina y Bio ecnología (Jun a de Andalucía-
Uni e sidad de Málaga), Málaga 29590, Spain
Ana M. Bel án−Depa amen o de Ingenie ía y Ciencia de
Los Ma e iales y Del T anspo e, Escuela Poli écnica
Supe io , Uni e sidad de Se illa, Se illa 41011, Spain;
o cid.o g/0000-0003-2599-5908
Comple e con ac in o ma ion is a ailable a :
h ps://pubs.acs.o g/10.1021/acsanm.1c00569
Au ho Con ibu ions
All au ho s con ibu ed o he w i ing o he manusc ip . The
final e sion o he manusc ip has been app o ed by all
au ho s. C.C. and J.M.P.-M. con ibu ed equally o his wo k.
Funding
Financial suppo was p o ided by he Minis y o Economy,
Indus y and Compe i i eness o he Spanish Go e nmen ,
g an CTQ2017-86655-R o MLGM and MPL; and he
Minis y o Heal h o he Andalusian Regional Go e nmen ,
g an OH-0026-2018 o MLGM and g an PI2013-0559 o
MPL.
No es
The au ho s decla e no compe ing financial in e es .
The aw/p ocessed da a equi ed o ep oduce hese findings
canno be sha ed a his ime as he da a also o ms pa o an
ongoing s udy.
■ACKNOWLEDGMENTS
The au ho s wan o exp ess special hanks o Alejand o
Domínguez o his in aluable help wi h he in i o oxici y
expe imen s. The au ho s also hank D . Juan F. López o his
suppo wi h he TEM expe imen s, D . Inaki O ue o VSM
measu emen , D . John Pea son and Luisa Macías o
assis ance wi h he cell expe imen s and help ul discussion,
Reyes Molina o assis ance wi h animal expe imen s, and
Ma ia Somoza o helping wi h he MRI expe imen s. Au ho s
hank BIONAND’s Nanoimaging Uni . Op ical mic oscopy,
TEM, CT, and MRI expe imen s ha e been pe o med in he
ICTS “NANBIOSIS”, mo e specifically in he U28 Uni a
BIONAND.
■REFERENCES
(1) Runge, V. M.; Aoki, S.; B adley, W. G., J .; Chang, K.-H.; Essig,
M.; Ma, L.; Ross, J. S.; Vala anis, A. Magne ic Resonance Imaging and
Compu ed Tomog aphy o he B ain-50 Yea s o Inno a ion, Wi h a
Focus on he Fu u e. In es . Radiol. 2015,50, 551−556.
(2) Campbell, B. C. V.; Ch is ensen, S.; Le i, C. R.; Desmond, P.
M.; Donnan, G. A.; Da is, S. M.; Pa sons, M. W. Compa ison o
compu ed omog aphy pe usion and magne ic esonance imaging
pe usion-di usion misma ch in ischemic s oke. S oke 2012,43,
2648−2653.
(3) Xiao, Y.-D.; Paudel, R.; Liu, J.; Ma, C.; Zhang, Z.-S.; Zhou, S.-K.
MRI con as agen s: Classi ica ion and applica ion (Re iew). In . J.
Mol. Med. 2016,38, 1319−1326.
(4) Wa hen, C.; Foje, N.; A e mae e, T.; Mi amon es, B.;
Chapaman, S.; Sasse , T.; Kannan, R.; Ge s le , S.; Lee y, W. In
i o X-Ray Compu ed Tomog aphic Imaging o So Tissue wi h
Na i e, In a enous, o O al Con as . Senso s 2013,13, 6957−6980.
(5) Lusic, H.; G ins a , M. W. X- ay-compu ed omog aphy con as
agen s. Chem. Re . 2013,113, 1641−1666.
(6) McDonald, R. J.; McDonald, J. S.; Kallmes, D. F.; Jen o , M. E.;
Mu ay, D. L.; Thielen, K. R.; Williamson, E. E.; Eckel, L. J.
In ac anial Gadolinium Deposi ion a e Con as -enhanced MR
Imaging. Radiology 2015,275, 772−782.
(7) Rogosni zky, M.; B anch, S. Gadolinium-based con as agen
oxici y: a e iew o known and p oposed mechanisms. BioMe als
2016,29, 365−376.
(8) E soy, H.; Rybicki, F. J. Biochemical sa e y p o iles o
gadolinium-based ex acellula con as agen s and neph ogenic
sys emic ib osis. J. Magn. Reson. Imag. 2007,26, 1190−1197.
(9) Cha, M. J.; Kang, D. Y.; Lee, W.; Yoon, S. H.; Choi, Y. H.; Byun,
J. S.; Lee, J.; Kim, Y.-H.; Choo, K. S.; Cho, B. S.; Jeon, K. N.; Jung, J.-
W.; Kang, H.-R. Hype sensi i i y Reac ions o Iodina ed Con as
Media: A Mul icen e S udy o 196 081 Pa ien s. Radiology 2019,293,
117−124.
(10) S acul, F.; an de Molen, A. J.; Reime , P.; Webb, J. A.;
Thomsen, H. S.; Mo cos, S. K.; Almen, T.; Aspelin, P.; Bellin, M. F.;
Clemen , O.; Heinz-Pee , G. Con as induced neph opa hy: upda ed
ESUR Con as Media Sa e y Commi ee guidelines. Eu . Radiol.
2011,21, 2527−2541.
(11) A ia, M. F.; An on, N.; Akaso , R.; Chipe , M.; Ma k iche a,
E.; Vandamme, T. F. Biodis ibu ion and Toxici y o X-Ray Iodina ed
Con as Agen in Nano-emulsions in Func ion o Thei Size. Pha m.
Res. 2016,33, 603−614.
(12) Roco, M. C.; Mi kin, C. A.; He sam, M. C. Nano echnology
esea ch di ec ions o socie al needs in 2020: summa y o
in e na ional s udy. J. Nanopa icle Res. 2011,13, 897−919.
(13) A as hi, A.; Ca o, C.; Pozo-To es, E.; Leal, M. P.; Ga cía-
Ma ín, M. L. Magne ic Nanopa icles as MRI Con as Agen s. Top.
Cu . Chem. 2020,378, 40.
(14) Lee, N.; Choi, S. H.; Hyeon, T. Nano-sized CT con as agen s.
Ad . Ma e . 2013,25, 2641−2660.
(15) Escude o, A.; Bece o, A. I.; Ca illo-Ca ión, C.; Nunez, N. O.;
Zyuzin, M. V.; Laguna, M.; González-Mancebo, D.; Ocana, M.; Pa ak,
W. J. Ra e ea h based nanos uc u ed ma e ials: syn hesis,
unc ionaliza ion, p ope ies and bioimaging and biosensing applica-
ions. Nanopho onics 2017,6, 881.
(16) Tian, Y.; Yang, H.-Y.; Li, K.; Jin, X. Monodispe sed ul a hin
GdF3 nanowi es: o ien ed a achmen , luminescence, and elaxi i y
o MRI con as agen s. J. Ma e . Chem. 2012,22, 22510−22516.
(17) Zai o , R.; Khakimullina, G.; Podyache , S.; Nizamee , I.;
Sa iullin, G.; Ami o , R.; Vomie o, A.; Mus a ina, A. Hyd a ion
numbe : c ucial ole in nuclea magne ic elaxi i y o Gd(III) chela e-
based nanopa icles. Sci. Rep. 2017,7, 14010.
(18) Kang, X.; Yang, D.; Ma, P.; Dai, Y.; Shang, M.; Geng, D.;
Cheng, Z.; Lin, J. Fab ica ion o Hollow and Po ous S uc u ed
GdVO4:Dy3+ Nanosphe es as An icance D ug Ca ie and MRI
Con as Agen . Langmui 2013,29, 1286−1294.
(19) Zai o , R.; Pizzanelli, S.; Do zhenko, A. P.; Nizamee , I.;
O ekho , A.; A kha o a, N.; Podyache , S. N.; Sudako a, S.;
Mus a ina, A. R.; Calucci, L. Pa amagne ic Relaxa ion Enhancemen
in Hyd ophilic Colloids Based on Gd(III) Complexes wi h Te a hia-
and Calix[4]a enes. J. Phys. Chem. C 2020,124, 4320−4329.
(20) González-Mancebo, D.; Bece o, A. I.; Rojas, T. C.; Ga cía-
Ma ín, M. L.; de la Fuen e, J. M.; Ocana, M. HoF3 and DyF3
Nanopa icles as Con as Agen s o High-Field Magne ic Resonance
Imaging. Pa . Pa . Sys . Cha . 2017,34, 1700116.
(21) G oman, E. V.; Boucha d, J. C.; Reinha d , C. P.; Vacca o, D. E.
Ul asmall mixed e i e colloids as mul idimensional magne ic
ACS Applied Nano Ma e ials www.acsanm.o g A icle
h ps://doi.o g/10.1021/acsanm.1c00569
ACS Appl. Nano Ma e . 2021, 4, 4199−4207
4206
esonance imaging, cell labeling, and cell so ing agen s. Bioconjuga e
Chem. 2007,18, 1763−1771.
(22) Chen, F.; Chen, M.; Yang, C.; Liu, J.; Luo, N.; Yang, G.; Chen,
D.; Li, L. Te bium-doped gadolinium oxide nanopa icles p epa ed by
lase abla ion in liquid o use as a luo escence and magne ic
esonance imaging dual-modal con as agen . Phys. Chem. Chem.
Phys. 2015,17, 1189−1196.
(23) Biju, V.; Hamada, M.; Ono, K.; Sugino, S.; Ohnishi, T.; Shibu,
E. S.; Yamamu a, S.; Sawada, M.; Nakanishi, S.; Shige i, Y.; Wakida,
S.-i. Nanopa icles speckled by eady- o-conjuga e lan hanide
complexes o mul imodal imaging. Nanoscale 2015,7, 14829−14837.
(24) Liu, K.; Shi, X.; Wang, T.; Ai, P.; Gu, W.; Ye, L. Te bium-
doped manganese ca bona e nanopa icles wi h in insic pho o-
luminescence and magne ic esonance imaging capaci y. J. Colloid
In e ace Sci. 2017,485,25−31.
(25) González-Mancebo, D.; Bece o, A. I.; Co al, A.; Ga cía-
Embid, S.; Balce zyk, M.; Ga cia-Ma in, M. L.; de la Fuen e, J. M.;
Ocana, M. Design o a nanop obe o high ield magne ic esonance
imaging, dual ene gy X- ay compu ed omog aphy and luminescen
imaging. J. Colloid In e ace Sci. 2020,573, 278−286.
(26) Ocana, M.; Nunez, N. O.; Bece o, A. I.; Lozano, G.; Mo os,
M.; de la Fuen e, J. M.; Co al, A.; Balce zyk, M.; Ocana, M.
Syn hesis, unc ionaliza ion and p ope ies o uni o m eu opium-
doped sodium lan hanum ungs a e and molybda e (NaLa(XO4)2,
X=Mo,W) p obes o luminescen and X- ay compu ed omog aphy
bioimaging. J. Colloid In e ace Sci. 2019,554, 520−530.
(27) Ocana, A.; Vidal-Moya, A.; Be nabeu, A.; Pacheco-To es, J.;
Checa-Cha a ia,E.;Fe nández,E.;Bo ella,P.Gd-SiOxide
Nanopa icles as Con as Agen s in Magne ic Resonance Imaging.
Nanoma e ials (Basel) 2016,6, 109.
(28) Miao, X.; Ho, S. L.; Tega aw, T.; Cha, H.; Chang, Y.; Oh, I. T.;
Yaseen, A. M.; Ma asini, S.; Ghazan a i, A.; Yue, H.; Chae, K. S.; Lee,
G. H. S able and non- oxic ul asmall gadolinium oxide nanopa icle
colloids (coa ing ma e ial = polyac ylic acid) as high-pe o mance T1
magne ic esonance imaging con as agen s. RSC Ad . 2018,8,
3189−3197.
(29) Zhao, Z.; Xu, K.; Fu, C.; Liu, H.; Lei, M.; Bao, J.; Fu, A.; Yu, Y.;
Zhang, W. In e acial enginee ed gadolinium oxide nanopa icles o
magne ic esonance imaging guided mic oen i onmen -media ed
syne ge ic chemodynamic/pho o he mal he apy. Bioma e ials 2019,
219, 119379.
(30) Bony, B. A.; Mille , H. A.; Ta udji, A. W.; Gee, C. C.; Sa ella,
A.; Nichols, M. G.; Kie i , F. M. Ul asmall Mixed Eu−Gd Oxide
Nanopa icles o Mul imodal Fluo escence and Magne ic Resonance
Imaging o Passi e Accumula ion and Re en ion in TBI. ACS Omega
2020,5, 16220−16227.
(31) Ma asini, S.; Yue, H.; Ho, S. L.; Jung, K.-H.; Pa k, J. A.; Cha,
H.; Ghazan a i, A.; Ahmad, M. Y.; Liu, S.; Jang, Y. J.; Miao, X.; Chae,
K.-S.; Chang, Y.; Lee, G. H. d-Glucu onic Acid-Coa ed Ul asmall
Pa amagne ic Ln2O3 (Ln = Tb, Dy, and Ho) Nanopa icles:
Magne ic P ope ies, Wa e P o on Relaxi i ies, and Fluo escence
P ope ies. Eu . J. Ino g. Chem. 2019,2019, 3832−3839.
(32) Yi, Z.; Li, X.; Lu, W.; Liu, H.; Zeng, S.; Hao, J. Hyb id
lan hanide nanopa icles as a new class o bina y con as agen s o in
i o T1/T2 dual-weigh ed MRI and syne gis ic umo diagnosis. J.
Ma e . Chem. B 2016,4, 2715−2722.
(33) Pe nia Leal, M.; Ri e a-Fe nández, S.; F anco, J. M.; Pozo, D.;
de la Fuen e, J. M.; Ga cía-Ma ín, M. L. Long-ci cula ing PEGyla ed
manganese e i e nanopa icles o MRI-based molecula imaging.
Nanoscale 2015,7, 2050−2059.
(34) Ca o, C.; Ca men Munoz-He nández, M.; Leal, M. P.; Ga cía-
Ma ín, M. L. In Vi o Pha macokine ics o Magne ic Nanopa icles.
Me hods Mol. Biol. 2018,1718, 409−419.
(35) Pe nia Leal, M.; Ca o, C.; Ga cía-Ma ín, M. L. Shedding ligh
on zwi e ionic magne ic nanopa icles: limi a ions o in i o
applica ions. Nanoscale 2017,9, 8176−8184.
(36) Pozo-To es, E.; Ca o, C.; A as hi, A.; Páez-Munoz, J. M.;
Ga cía-Ma ín, M. L.; Fe nández, I.; Pe nia Leal, M. Clickable i on
oxide NPs based on ca echol de i ed ligands: syn hesis and
cha ac e iza ion. So Ma e 2020,16, 3257−3266.
(37) He e n, M. C.; Ma osziuk, L. M.; Meade, T. J. Lan hanide
p obes o bio esponsi e imaging. Chem. Re . 2014,114, 4496−4539.
(38) Di Be na do, P.; Zanona o, P. L.; Bismondo, A.; Melchio , A.;
Tolazzi, M. P o ona ion and lan hanide(III) complexa ion equilib ia
o a new ipodal polyaza-polyca echol-amine. Dal on T ans. 2009,
4236−4244.
(39) Tang, Q.; Shen, J.; Zhou, W.; Zhang, W.; Yu, W.; Qian, Y.
P epa a ion, cha ac e iza ion and op ical p ope ies o e bium oxide
nano ubes. J. Ma e . Chem. 2003,13, 3103−3106.
(40) Ca o, C.; Dalmases, M.; Figue ola, A.; Ga cía-Ma ín, M. L.;
Leal, M. P. Highly wa e -s able a e e na y Ag-Au-Se nanocomposi es
as long blood ci cula ion ime X- ay compu ed omog aphy con as
agen s. Nanoscale 2017,9, 7242−7251.
(41) Jun, Y. W.; Kim, H. R.; Reo, Y. J.; Dai, M.; Ahn, K. H.
Add essing he au o luo escence issue in deep issue imaging by wo-
pho on mic oscopy: he signi icance o a - ed emi ing dyes. Chem.
Sci. 2017,8, 7696−7704.
(42) Ca o, C.; Egea-Bena en e, D.; Pol illo, R.; Royo, J. L.; Pe nia
Leal, M.; Ga cía-Ma ín, M. L. Comp ehensi e Toxici y Assessmen o
PEGyla ed Magne ic Nanopa icles o in i o applica ions. Colloids
Su . B Bioin e aces 2019,177, 253−259.
(43) Guo, Y.; Chen, L.; Wu, J.; Hua, J.; Yang, L.; Wang, Q.; Zhang,
W.; Lee, J.-S.; Zhou, B. Pa en al co-exposu e o bisphenol A and
nano-TiO2 causes hy oid endoc ine dis up ion and de elopmen al
neu o oxici y in zeb a ish o sp ing. Sci. To al En i on. 2019,650,
557−565.
(44) Xiao, Y.; Zeng, G.; Liu, X.; Peng, C.; Lai, C.; Zhou, P. Sa e y
enhancemen in adul body compu ed omog aphy scanning:
compa ison o iodixanol e sus iohexol. Sp inge plus 2016,5, 148.
(45) Pe aul , S. D.; Walkey, C.; Jennings, T.; Fische , H. C.; Chan,
W. C. W. Media ing umo a ge ing e iciency o nanopa icles
h ough design. Nano Le . 2009,9, 1909−1915.
(46) Pe e , A. I.; Naidu, E. C.; Akang, E.; Ogedengbe, O. O.; O o ,
U.; Rambha ose, S.; Kalhapu e, R.; Chu u goon, A.; Go ende , T.;
Azu, O. O. In es iga ing O gan Toxici y P o ile o Teno o i and
Teno o i Nanopa icle on he Li e and Kidney: Expe imen al
Animal S udy. Toxicol. Res. 2018,34, 221−229.
ACS Applied Nano Ma e ials www.acsanm.o g A icle
h ps://doi.o g/10.1021/acsanm.1c00569
ACS Appl. Nano Ma e . 2021, 4, 4199−4207
4207